22-May-2026
TipRanks (Thu, 21-May 6:16 AM ET)
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Business Wire (Tue, 12-May 8:00 AM ET)
Business Wire (Thu, 7-May 8:00 AM ET)
Business Wire (Thu, 5-Mar 7:30 AM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of May 22, 2026, SLN stock price declined to $6.20 with 254,754 million shares trading.
SLN has a beta of 1.99, meaning it tends to be more sensitive to market movements. SLN has a correlation of 0.07 to the broad based SPY ETF.
SLN has a market cap of $292.73 million. This is considered a Small Cap stock.
Last quarter Silence Therapeutics PLC - American Depository Share reported $422,000 in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.10.
In the last 3 years, SLN traded as high as $27.72 and as low as $1.97.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, GWX, APIE, IBBQ, BIB.
SLN has underperformed the market in the last year with a price return of +28.1% while the SPY ETF gained +29.1%. However, in the short term, SLN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +24.0% vs +8.4% return in SPY. But in the last 2 weeks, SLN shares have been beat by the market, returning -11.0% compared to an SPY return of +1.1%.
SLN support price is $6.14 and resistance is $6.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.